Symbols / ALLO $2.39 +3.02% Allogene Therapeutics, Inc.
ALLO Chart
About
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Market Cap | 822.11M | Enterprise Value | 415.67M | Income | -190.89M | Sales | — | Book/sh | 1.27 | Cash/sh | 1.03 |
| Dividend Yield | — | Payout | 0.00% | Employees | 150 | IPO | — | P/E | — | Forward P/E | -3.19 |
| PEG | — | P/S | — | P/B | 1.87 | P/C | — | EV/EBITDA | -2.14 | EV/Sales | — |
| Quick Ratio | 7.74 | Current Ratio | 7.93 | Debt/Eq | 28.46 | LT Debt/Eq | — | EPS (ttm) | -0.87 | EPS next Y | -0.75 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-15 | ROA | -26.82% | ROE | -53.42% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 343.98M | Shs Float | 203.75M | Short Float | 15.59% |
| Short Ratio | 5.87 | Short Interest | — | 52W High | 4.46 | 52W Low | 0.86 | Beta | 0.54 | Avg Volume | 9.63M |
| Volume | 9.42M | Target Price | $8.65 | Recom | Strong_buy | Prev Close | $2.32 | Price | $2.39 | Change | 3.02% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | up | JP Morgan | Underweight → Neutral | — |
| 2026-04-16 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-04-15 | main | Jefferies | Buy → Buy | $10 |
| 2026-04-14 | main | Bernstein | Market Perform → Market Perform | $4 |
| 2026-04-14 | main | Argus Research | Market Perform → Market Perform | $4 |
| 2026-04-14 | main | Citizens | Market Outperform → Market Outperform | $8 |
| 2026-04-14 | main | Baird | Outperform → Outperform | $9 |
| 2026-04-14 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-03-13 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2026-03-13 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2026-01-09 | up | Citizens | Market Perform → Market Outperform | $5 |
| 2026-01-07 | init | UBS | — → Buy | $8 |
| 2025-10-10 | down | JP Morgan | Neutral → Underweight | — |
| 2025-08-04 | reit | JMP Securities | Market Perform → Market Perform | — |
| 2025-08-04 | down | JP Morgan | Overweight → Neutral | — |
| 2025-08-01 | main | Oppenheimer | Outperform → Outperform | $7 |
| 2025-05-15 | main | Citigroup | Buy → Buy | $4 |
| 2025-05-14 | main | Truist Securities | Buy → Buy | $10 |
| 2025-05-14 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2025-05-14 | reit | RBC Capital | Outperform → Outperform | $10 |
- Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan Wed, 22 Apr 2026 00
- Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? - Yahoo Finance Sun, 12 Apr 2026 07
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - ChartMill ue, 21 Apr 2026 12
- ALLO Stock Spikes As ALPHA3 CAR‑T Data Resets Expectations - timothysykes.com hu, 16 Apr 2026 18
- Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus ue, 21 Apr 2026 16
- Allogene Therapeutics Stock Soars 12% On Positive Phase 2 Data For Lymphoma Treatment - TIKR.com ue, 14 Apr 2026 12
- ALLO Stock Soars As ALPHA3 CAR‑T Data Reprices The Story - StocksToTrade hu, 16 Apr 2026 17
- $ALLO stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 19
- Allogene sold 100.2M shares at $2, bringing in $200.4M - Stock Titan hu, 16 Apr 2026 20
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 26 Jan 2026 08
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - ChartMill Mon, 20 Apr 2026 12
- ALLO Stock Soars As ALPHA3 Trial Data Reset Expectations - timothysykes.com hu, 16 Apr 2026 15
- If You Invested $1,000 in Allogene Therapeutics (ALLO) - Stock Titan Sun, 22 Mar 2026 11
- ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com hu, 16 Apr 2026 21
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - ChartMill hu, 16 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
0.02
-76.84%
|
0.10
-39.10%
|
0.16
|
| Operating Revenue |
|
0.00
-100.00%
|
0.02
-76.84%
|
0.10
-39.10%
|
0.16
|
| Operating Expense |
|
206.93
-19.64%
|
257.50
-18.15%
|
314.59
-6.29%
|
335.69
|
| Research And Development |
|
150.15
-21.92%
|
192.30
-20.84%
|
242.91
-5.25%
|
256.39
|
| Selling General And Administration |
|
56.78
-12.92%
|
65.20
-9.02%
|
71.67
-9.62%
|
79.31
|
| General And Administrative Expense |
|
56.78
-12.92%
|
65.20
-9.02%
|
71.67
-9.62%
|
79.31
|
| Other Gand A |
|
56.78
-12.92%
|
65.20
-9.02%
|
71.67
-9.62%
|
79.31
|
| Total Expenses |
|
206.93
-19.64%
|
257.50
-18.15%
|
314.59
-6.29%
|
335.69
|
| Operating Income |
|
-206.93
+19.63%
|
-257.48
+18.13%
|
-314.49
+6.27%
|
-335.54
|
| Total Operating Income As Reported |
|
-209.31
+23.38%
|
-273.20
+16.64%
|
-327.74
+2.32%
|
-335.54
|
| EBITDA |
|
-177.45
+27.07%
|
-243.33
+22.28%
|
-313.07
+2.54%
|
-321.24
|
| Normalized EBITDA |
|
-175.07
+23.08%
|
-227.61
+24.08%
|
-299.82
+6.67%
|
-321.24
|
| Reconciled Depreciation |
|
12.36
-9.38%
|
13.64
-3.94%
|
14.20
-0.67%
|
14.29
|
| EBIT |
|
-189.81
+26.13%
|
-256.97
+21.48%
|
-327.26
+2.47%
|
-335.54
|
| Total Unusual Items |
|
-2.38
+84.84%
|
-15.72
-18.66%
|
-13.24
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-2.38
+84.84%
|
-15.72
-18.66%
|
-13.24
|
—
|
| Special Income Charges |
|
-2.38
+84.84%
|
-15.72
-18.66%
|
-13.24
|
—
|
| Impairment Of Capital Assets |
|
2.38
-84.84%
|
15.72
+18.66%
|
13.24
|
—
|
| Net Income |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Pretax Income |
|
-190.89
+25.77%
|
-257.15
+21.43%
|
-327.26
+3.86%
|
-340.41
|
| Net Non Operating Interest Income Expense |
|
18.21
-8.80%
|
19.97
+9.09%
|
18.31
+300.94%
|
4.57
|
| Interest Expense Non Operating |
|
1.07
+493.92%
|
0.18
|
0.00
|
—
|
| Net Interest Income |
|
18.21
-8.80%
|
19.97
+9.09%
|
18.31
+300.94%
|
4.57
|
| Interest Expense |
|
1.07
+493.92%
|
0.18
|
0.00
|
—
|
| Interest Income Non Operating |
|
19.29
-4.29%
|
20.15
+10.08%
|
18.31
+300.94%
|
4.57
|
| Interest Income |
|
19.29
-4.29%
|
20.15
+10.08%
|
18.31
+300.94%
|
4.57
|
| Other Income Expense |
|
-2.17
+88.96%
|
-19.64
+36.82%
|
-31.08
-229.10%
|
-9.44
|
| Other Non Operating Income Expenses |
|
0.21
+105.48%
|
-3.92
+78.02%
|
-17.84
-88.85%
|
-9.44
|
| Tax Provision |
|
0.00
-100.00%
|
0.44
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-3.30
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Net Income From Continuing Operation Net Minority Interest |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Net Income From Continuing And Discontinued Operation |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Net Income Continuous Operations |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Normalized Income |
|
-188.50
+23.11%
|
-245.17
+21.92%
|
-314.02
+7.75%
|
-340.41
|
| Net Income Common Stockholders |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Diluted EPS |
|
—
|
-1.32
+36.84%
|
-2.09
+9.91%
|
-2.32
|
| Basic EPS |
|
—
|
-1.32
+36.84%
|
-2.09
+9.91%
|
-2.32
|
| Basic Average Shares |
|
—
|
194.81
+24.14%
|
156.93
+9.63%
|
143.15
|
| Diluted Average Shares |
|
—
|
194.81
+24.14%
|
156.93
+9.63%
|
143.15
|
| Diluted NI Availto Com Stockholders |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
415.90
-24.20%
|
548.71
-14.64%
|
642.84
-21.76%
|
821.58
|
| Current Assets |
|
257.75
-15.04%
|
303.39
-33.92%
|
459.12
-13.18%
|
528.82
|
| Cash Cash Equivalents And Short Term Investments |
|
250.21
-14.45%
|
292.48
-34.82%
|
448.70
-13.27%
|
517.32
|
| Cash And Cash Equivalents |
|
51.69
-31.28%
|
75.22
-9.54%
|
83.16
+34.33%
|
61.90
|
| Cash Equivalents |
|
—
|
—
|
78.54
|
—
|
| Cash Financial |
|
—
|
—
|
4.62
|
—
|
| Other Short Term Investments |
|
198.52
-8.62%
|
217.26
-40.57%
|
365.54
-19.73%
|
455.42
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
7.54
-30.90%
|
10.91
+4.72%
|
10.42
-9.44%
|
11.50
|
| Total Non Current Assets |
|
158.16
-35.53%
|
245.32
+33.53%
|
183.72
-37.24%
|
292.75
|
| Net PPE |
|
112.73
-14.12%
|
131.26
-19.56%
|
163.18
-16.93%
|
196.43
|
| Gross PPE |
|
185.26
-4.41%
|
193.80
-9.55%
|
214.26
-8.17%
|
233.32
|
| Accumulated Depreciation |
|
-72.53
-15.98%
|
-62.54
-22.42%
|
-51.08
-38.50%
|
-36.88
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
9.09
+2.42%
|
8.87
+1.00%
|
8.78
+2.80%
|
8.54
|
| Construction In Progress |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Other Properties |
|
68.64
-10.63%
|
76.80
-20.71%
|
96.86
-16.64%
|
116.19
|
| Leases |
|
107.54
-0.55%
|
108.13
-0.45%
|
108.62
+0.07%
|
108.55
|
| Investments And Advances |
|
8.04
-90.03%
|
80.67
+2113.25%
|
3.65
-95.23%
|
76.47
|
| Long Term Equity Investment |
|
—
|
0.00
-100.00%
|
3.65
-78.95%
|
17.32
|
| Other Non Current Assets |
|
37.39
+11.97%
|
33.39
+97.62%
|
16.90
-14.91%
|
19.86
|
| Total Liabilities Net Minority Interest |
|
123.36
-2.50%
|
126.53
-3.12%
|
130.60
-15.57%
|
154.70
|
| Current Liabilities |
|
32.51
-8.47%
|
35.52
-4.20%
|
37.08
-30.99%
|
53.73
|
| Payables And Accrued Expenses |
|
14.06
-11.36%
|
15.87
-9.60%
|
17.55
-40.89%
|
29.70
|
| Payables |
|
4.27
-20.84%
|
5.39
-8.53%
|
5.90
-57.54%
|
13.89
|
| Accounts Payable |
|
4.27
-20.84%
|
5.39
-8.53%
|
5.90
-57.54%
|
13.89
|
| Current Accrued Expenses |
|
9.79
-6.48%
|
10.47
-10.14%
|
11.66
-26.26%
|
15.81
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
10.24
-15.68%
|
12.15
-4.10%
|
12.66
-29.38%
|
17.93
|
| Current Debt And Capital Lease Obligation |
|
8.21
+9.31%
|
7.51
+10.83%
|
6.78
+12.88%
|
6.00
|
| Current Capital Lease Obligation |
|
8.21
+9.31%
|
7.51
+10.83%
|
6.78
+12.88%
|
6.00
|
| Current Deferred Liabilities |
|
—
|
—
|
0.09
-9.47%
|
0.10
|
| Current Deferred Revenue |
|
—
|
—
|
0.09
-9.47%
|
0.10
|
| Other Current Liabilities |
|
—
|
—
|
0.09
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
90.85
-0.17%
|
91.01
-2.69%
|
93.53
-7.37%
|
100.97
|
| Long Term Debt And Capital Lease Obligation |
|
75.05
-9.85%
|
83.25
-5.77%
|
88.35
-7.12%
|
95.12
|
| Long Term Capital Lease Obligation |
|
75.05
-9.85%
|
83.25
-5.77%
|
88.35
-7.12%
|
95.12
|
| Other Non Current Liabilities |
|
15.80
+103.63%
|
7.76
+49.86%
|
5.18
-11.42%
|
5.85
|
| Stockholders Equity |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Common Stock Equity |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Capital Stock |
|
0.23
+8.02%
|
0.21
+25.44%
|
0.17
+17.36%
|
0.14
|
| Common Stock |
|
0.23
+8.02%
|
0.21
+25.44%
|
0.17
+17.36%
|
0.14
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
229.41
+8.11%
|
212.21
+25.83%
|
168.64
+16.76%
|
144.44
|
| Ordinary Shares Number |
|
229.41
+8.11%
|
212.21
+25.83%
|
168.64
+16.76%
|
144.44
|
| Additional Paid In Capital |
|
2,302.75
+2.72%
|
2,241.88
+8.03%
|
2,075.25
+8.56%
|
1,911.63
|
| Retained Earnings |
|
-2,010.71
-10.49%
|
-1,819.82
-16.49%
|
-1,562.23
-26.50%
|
-1,234.97
|
| Gains Losses Not Affecting Retained Earnings |
|
0.27
+402.25%
|
-0.09
+90.68%
|
-0.95
+90.38%
|
-9.93
|
| Other Equity Adjustments |
|
0.27
+402.25%
|
-0.09
+90.68%
|
-0.95
+90.38%
|
-9.93
|
| Total Equity Gross Minority Interest |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Total Capitalization |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Working Capital |
|
225.24
-15.91%
|
267.86
-36.53%
|
422.04
-11.17%
|
475.10
|
| Invested Capital |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Total Debt |
|
83.25
-8.27%
|
90.76
-4.59%
|
95.12
-5.94%
|
101.12
|
| Capital Lease Obligations |
|
83.25
-8.27%
|
90.76
-4.59%
|
95.12
-5.94%
|
101.12
|
| Net Tangible Assets |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Tangible Book Value |
|
292.54
-30.71%
|
422.18
-17.58%
|
512.23
-23.19%
|
666.88
|
| Available For Sale Securities |
|
8.04
-90.03%
|
80.67
|
—
|
59.15
|
| Investmentin Financial Assets |
|
8.04
-90.03%
|
80.67
|
0.00
-100.00%
|
59.15
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-149.25
+25.49%
|
-200.30
+15.75%
|
-237.73
-7.81%
|
-220.52
|
| Cash Flow From Continuing Operating Activities |
|
-149.25
+25.49%
|
-200.30
+15.75%
|
-237.73
-7.81%
|
-220.52
|
| Net Income From Continuing Operations |
|
-190.89
+25.90%
|
-257.59
+21.29%
|
-327.26
+3.86%
|
-340.41
|
| Depreciation Amortization Depletion |
|
12.36
-9.38%
|
13.64
-3.94%
|
14.20
-0.67%
|
14.29
|
| Depreciation |
|
—
|
—
|
—
|
14.29
|
| Amortization Cash Flow |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization |
|
12.36
-9.38%
|
13.64
-3.94%
|
14.20
-0.67%
|
14.29
|
| Amortization Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Other Non Cash Items |
|
4.36
-17.05%
|
5.25
-20.22%
|
6.58
+182.57%
|
2.33
|
| Stock Based Compensation |
|
37.64
-27.25%
|
51.74
-21.54%
|
65.95
-21.11%
|
83.60
|
| Asset Impairment Charge |
|
2.38
-86.52%
|
17.67
-12.70%
|
20.25
|
—
|
| Deferred Tax |
|
0.00
-100.00%
|
0.44
|
0.00
|
—
|
| Deferred Income Tax |
|
0.00
-100.00%
|
0.44
|
0.00
|
—
|
| Operating Gains Losses |
|
—
|
1.69
-84.18%
|
10.67
-17.16%
|
12.88
|
| Change In Working Capital |
|
-10.88
+56.14%
|
-24.80
-16.39%
|
-21.31
-646.75%
|
3.90
|
| Change In Prepaid Assets |
|
3.24
+758.13%
|
-0.49
-145.30%
|
1.09
-56.85%
|
2.52
|
| Change In Payables And Accrued Expense |
|
-3.75
-112.52%
|
-1.76
+87.68%
|
-14.32
-316.49%
|
6.62
|
| Change In Accrued Expense |
|
-2.52
-99.68%
|
-1.26
+81.50%
|
-6.82
-490.11%
|
1.75
|
| Change In Payable |
|
-1.23
-144.73%
|
-0.50
+93.30%
|
-7.50
-254.11%
|
4.87
|
| Change In Account Payable |
|
-1.23
-144.73%
|
-0.50
+93.30%
|
-7.50
-254.11%
|
4.87
|
| Change In Other Working Capital |
|
-2.71
+86.97%
|
-20.77
-692333.33%
|
-0.00
+85.71%
|
-0.02
|
| Change In Other Current Assets |
|
-1.29
-130.15%
|
4.28
+394.09%
|
-1.46
+56.36%
|
-3.33
|
| Change In Other Current Liabilities |
|
-6.37
-5.29%
|
-6.05
+8.54%
|
-6.61
-251.38%
|
-1.88
|
| Investing Cash Flow |
|
95.56
+26.25%
|
75.69
-53.65%
|
163.29
+53.82%
|
106.16
|
| Cash Flow From Continuing Investing Activities |
|
95.56
+26.25%
|
75.69
-53.65%
|
163.29
+53.82%
|
106.16
|
| Net PPE Purchase And Sale |
|
-0.39
+44.38%
|
-0.69
+54.22%
|
-1.52
+70.80%
|
-5.19
|
| Purchase Of PPE |
|
-0.39
+44.38%
|
-0.69
+54.22%
|
-1.52
+70.80%
|
-5.19
|
| Capital Expenditure |
|
-0.39
+44.38%
|
-0.69
+54.22%
|
-1.52
+70.80%
|
-5.19
|
| Net Investment Purchase And Sale |
|
95.94
+25.61%
|
76.38
-53.65%
|
164.81
+48.01%
|
111.35
|
| Purchase Of Investment |
|
-138.26
+61.75%
|
-361.48
+17.59%
|
-438.63
-76.79%
|
-248.11
|
| Sale Of Investment |
|
234.20
-46.51%
|
437.86
-27.44%
|
603.43
+67.87%
|
359.46
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
30.16
-74.15%
|
116.67
+21.92%
|
95.69
+3143.90%
|
2.95
|
| Cash Flow From Continuing Financing Activities |
|
30.16
-74.15%
|
116.67
+21.92%
|
95.69
+3143.90%
|
2.95
|
| Net Common Stock Issuance |
|
22.35
-80.05%
|
112.05
+22.98%
|
91.11
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.90
-61.88%
|
2.35
-48.77%
|
4.58
+55.36%
|
2.95
|
| Net Other Financing Charges |
|
6.91
+202.98%
|
2.28
|
—
|
—
|
| Changes In Cash |
|
-23.53
-196.46%
|
-7.94
-137.35%
|
21.25
+119.07%
|
-111.41
|
| Beginning Cash Position |
|
85.51
-8.49%
|
93.45
+29.44%
|
72.20
-60.68%
|
183.61
|
| End Cash Position |
|
61.98
-27.52%
|
85.51
-8.49%
|
93.45
+29.44%
|
72.20
|
| Free Cash Flow |
|
-149.63
+25.55%
|
-200.99
+15.99%
|
-239.25
-6.00%
|
-225.71
|
| Amortization Of Securities |
|
-4.22
+49.44%
|
-8.35
-22.60%
|
-6.81
-335.52%
|
2.89
|
| Common Stock Issuance |
|
22.35
-80.05%
|
112.05
+22.98%
|
91.11
|
0.00
|
| Earnings Losses From Equity Investments |
|
0.00
-100.00%
|
1.69
-84.18%
|
10.67
-17.16%
|
12.88
|
| Issuance Of Capital Stock |
|
22.35
-80.05%
|
112.05
+22.98%
|
91.11
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-15 View
- 8-K2026-04-13 View
- 8-K2026-04-13 View
- 42026-04-02 View
- 42026-03-18 View
- 42026-03-18 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-03-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-23 View
- 42025-12-22 View
- 42025-11-19 View
- 10-Q2025-11-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|